Free Trial
NASDAQ:BMEA

Biomea Fusion Q2 2025 Earnings Report

Biomea Fusion logo
$1.58 -0.03 (-1.86%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.06 (+4.11%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Biomea Fusion's Q3 2025 earnings is scheduled for Wednesday, August 6, 2025

Biomea Fusion Earnings Headlines

Biomea Fusion (BMEA) Q2 Loss Drops 44%
Biomea Fusion files $300M mixed securities shelf
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

View Biomea Fusion Profile

More Earnings Resources from MarketBeat